Monotherapy with SG proved to be clinically efficacious in several different types of solid tumors, including SCLC, mTNBC, mHR+/HER2- BC, and mUC, with regular FDA approval in mTNBC, mHR+/HER2- BC, and accelerated approval for mUC [7–13]. Here, ERBB2 is linked to breast cancer.